← Back to Nuqta Atlas
Editorially curated · qa-genome2cure
Genome 2 Cure
Bedside-to-laboratory program that assembles deeply phenotyped genomic cohorts, diagnoses rare disease, and advances findings toward targeted interventions.
01 / Project overview
What the record establishes.
- Geographic scope
- Sidra Medicine national pediatric and family catchment
- Project type
- rare-disease translational genomics program
- Research domain
- Mendelian disease, metabolic disease, and precision genomics
- Years
- Not stated
- Lifecycle status
- active
- Status basis
- Sidra's current translational-research program page describes Genome 2 Cure and its ongoing Gold Cohorts, including newborn sequencing, type 1 diabetes, and other Mendelian disorders.
- Status evidence date
- 2026-08-15
- Scale
- No consolidated participant count; multiple Gold Cohorts cover newborn sequencing, type 1 diabetes, and other Mendelian diseases.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Sidra Medicine Metabolic and Mendelian Disorders Translational Research Program
- Partner organizations
- Hamad Medical Corporation and other clinical collaborators
- Organism / population
- Children and families with rare, Mendelian, metabolic, and selected autoimmune disorders
03 / Data and access
What exists and how it can be reached.
Data types
- whole-genome sequencing
- multi-omics
- deep phenotyping
- family data
- clinical outcomes
Data access
Institutional collaboration; no unified public cohort release identified.
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Named umbrella for multiple reusable rare-disease and Mendelian genomic cohorts.
Editorial note
Umbrella program. DANNA and NOOR-QATAR are recorded separately because they are named cohorts/screening initiatives.
Sources
- primary record source Verified 2026-08-15
Release v0.2.0